ORIC · Oric Pharmaceuticals, Inc.
Market Cap
$1.32B
Shares
103.65M
ORIC metrics
52 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$12.86
Market cap
$1.32B
Price action
19 metricsPrice change (1W)
-2.9%
Price change (30D)
-0.5%
Price change (3M)
+71.5%
Price change (6M)
-6.2%
Price change (YTD)
+57.2%
Price change (1Y)
+19.4%
Trailing year
Price change (5Y)
-44.1%
52-week high
$14.65
52-week low
$7.48
Change from 52-week high
-12.2%
Change from 52-week low
+72.0%
Annualized volatility
86.4%
Beta
1.5
RSI (14D)
48.9
Price vs SMA 50
+5.6%
Price vs SMA 200
+20.6%
Avg volume (3M)
1.56M
Relative volume
0.6
Average dollar volume
$17.35M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
103.65M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
3.5
reciprocal yield 28.9%
FCF yield
-8.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-10.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2022-03-21
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$156.14M
Net income (TTM)
−$140.35M
Trailing 12 months
Diluted EPS (TTM)
$-1.30
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-36.8%
Return on assets
-34.7%
Debt / equity
—
Current ratio
13.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$112.26M
Quick ratio
13.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$37.48M
Total assets
$404.69M
Total debt
$10.50M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$111.64M
Capital expenditures (TTM)
$620,000
R&D (TTM)
$122.36M
SG&A (TTM)
—
Stock compensation (TTM)
$25.90M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
181
13F filer change QoQ
-1
Institutional ownership
119.7%
Short interest
3 metricsShort interest
17.7%
Latest settlement · 11.0 days to cover
Days to cover
11.0d
Short-squeeze score
85 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1.21M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1796280
CUSIP
68622P109
13F (30d)
158 filings
158 filers
Visit website
Investor relations